InspireMD Launches CGuard Prime Stent System, Potentially Reducing Embolism Risk, with Analysts Predicting an Upside of 99.12%

InspireMD has launched its CGuard Prime carotid stent system in the US, following FDA approval. The device features a dual-layer structure, MicroNet mesh, and SmartFit technology to reduce the risk of early and late embolism. Based on analyst forecasts, the average target price is $4.50, implying a 99.12% upside from the current price. The company is optimistic about receiving FDA approval for its Seaguard Prime stent in Q3 2025, expected to drive significant demand.

Title: InspireMD Launches CGuard Prime Carotid Stent System in the US

InspireMD (NASDAQ:NSPR) has successfully launched its CGuard Prime carotid stent system in the United States following FDA premarket approval. The device, designed to significantly reduce the risk of early and late embolism, features a dual-layer structure, MicroNet mesh, and SmartFit technology.

The CGuard Prime combines an open-cell frame with the smallest mesh pore size available, effectively trapping potential emboli against arterial walls while maintaining external carotid artery perfusion. The system also incorporates MicroNet technology, a bio-stable mesh made from a single 20-micrometer Polyethylene Terephthalate strand, and SmartFit technology, which eliminates the need for tapered versions.

InspireMD's CEO, Marvin Slosman, stated, "Our U.S. commercial launch marks a pivotal milestone in InspireMD’s expansion history, having already secured double-digit market share across more than 30 countries." The company is preparing for the launch with a robust commercial team and operational infrastructure.

Based on analyst forecasts, the average target price for InspireMD Inc (NSPR) is $4.50, implying a 99.12% upside from the current price. The company is optimistic about receiving FDA approval for its Seaguard Prime stent in Q3 2025, which is expected to drive significant demand.

References
1. [https://www.massdevice.com/inspiremd-launches-carotid-stent-us/](https://www.massdevice.com/inspiremd-launches-carotid-stent-us/)
2. [https://ca.investing.com/news/company-news/inspiremd-launches-cguard-prime-carotid-stent-in-us-after-fda-approval-93CH-4094763](https://ca.investing.com/news/company-news/inspiremd-launches-cguard-prime-carotid-stent-in-us-after-fda-approval-93CH-4094763)
3. [https://www.gurufocus.com/news/2966038/inspiremd-nspr-launches-cguard-prime-carotid-stent-system-in-the-us-nspr-stock-news](https://www.gurufocus.com/news/2966038/inspiremd-nspr-launches-cguard-prime-carotid-stent-system-in-the-us-nspr-stock-news)
4. [https://www.investing.com/news/stock-market-news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-93CH-4128239](https://www.investing.com/news/stock-market-news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-93CH-4128239)